COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma

Cora N. Sternberg, Robert J. Motzer, Thomas E. Hutson, Toni K. Choueiri, Christian Kollmannsberger, Georg A. Bjarnason, Nathan Paul Nathan, Camillo Porta, Viktor Grünwald, Luca Dezzani, Jackie Han, Nizar M. Tannir

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

This post hoc analysis of the COMPARZ study (pazopanib, n = 557; sunitinib, n = 553) supported similar efficacy of first-line pazopanib and first-line sunitinib treatment in advanced renal cell carcinoma. Patients who required dose modifications because of toxicity received higher cumulative doses with longer time of treatment and had significantly better objective response rate, progression-free survival, and overall survival than patients with minimal toxicity.

Original languageEnglish (US)
Pages (from-to)425-435.e4
JournalClinical Genitourinary Cancer
Volume17
Issue number6
DOIs
StatePublished - Dec 2019

Keywords

  • First-line
  • Sunitinib
  • Tyrosine kinase inhibitor
  • VEGF
  • VEGFR

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint

Dive into the research topics of 'COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma'. Together they form a unique fingerprint.

Cite this